Yahoo Finance

Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract Infections

RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage ...
Yahoo Finance

Locus Technologies Releases the First Fully Integrated Software Suite for Water Quality, Water Compliance, and Water Sustainability Programs

MOUNTAIN VIEW, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Locus Technologies, the sustainability and Environmental Health and Safety (EHS) compliance software leader, announced the release of Locus ...
Morningstar

Locus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio

TAIPEI, Sept. 29, 2025 /PRNewswire/ -- Locus Cell (TWSE: 6891), a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding (MOU) with Australia-based Cambium ...
TMCnet

71% of Consumers Say Viral Trends Drive Purchases, Putting New Pressure on Retail Fulfillment, Finds Locus Robotics

Locus Robotics, the leader in Flexibility-First Warehouse Automation, today announced a national consumer study on how viral ...
PMLiVE

Locus Biosciences announces first patient treated in urinary tract infection trial

Locus Biosciences (Locus) has begun treating the first patient in its phase 2/3 trial of LBP-EC01, in partnership with the Biomedical Advanced Research and Development Authority (BARDA), for the ...